التفاصيل البيبلوغرافية
| العنوان: |
Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials. |
| المؤلفون: |
Sosenko, Jay M., Skyler, Jay S., Herold, Kevan C., Schatz, Desmond A., Haller, Michael J., Pugliese, Alberto, Cleves, Mario, Geyer, Susan, Rafkin, Lisa E., Matheson, Della, Palmer, Jerry P., Type 1 Diabetes TrialNet Study Group |
| المصدر: |
Diabetes; Aug2020, Vol. 69 Issue 8, p1827-1832, 6p |
| مصطلحات موضوعية: |
TYPE 1 diabetes, INSULIN, GLUCOSE tolerance tests, PLACEBOS, DIABETES, INSULIN therapy, THERAPEUTIC use of monoclonal antibodies, BLOOD sugar, C-peptide, COMPARATIVE studies, RESEARCH methodology, MEDICAL cooperation, PHARMACOKINETICS, RESEARCH, EVALUATION research, RANDOMIZED controlled trials |
| مستخلص: |
We assessed whether oral insulin slowed metabolic decline after 1 year of treatment in individuals at high risk for type 1 diabetes. Two oral insulin trials that did not show efficacy overall and had type 1 diabetes as the primary end point were analyzed: the Diabetes Prevention Trial-Type 1 (DPT-1) and the TrialNet oral insulin trials. Oral glucose tolerance tests at baseline and after 1 year of treatment were analyzed. Among those at high risk (with a Diabetes Prevention Trial-Type 1 Risk Score [DPTRS] ≥6.75), the area under the curve (AUC) C-peptide increased significantly from baseline to 1 year in each oral insulin group, whereas the AUC glucose increased significantly in each placebo group. At 1 year, the AUC C-peptide/AUC glucose (AUC Ratio) was significantly higher in the oral insulin group than in the placebo group in each trial (P < 0.05; P = 0.057 when adjusted for age in the TrialNet trial) and in both trials combined (P < 0.01 with or without adjustment for age). For a DPTRS <6.75, oral insulin groups did not differ from placebo groups in the AUC Ratio. The findings suggest that 1 year of treatment with oral insulin slows metabolic deterioration in individuals at high risk for type 1 diabetes. Moreover, the findings further suggest that metabolic end points can be useful adjuncts to the diagnostic end point in assessments of preventive treatments for the disorder. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes is the property of American Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder